| Literature DB >> 35909507 |
Jie Wang1, Tong Xue2, Haopeng Li1, Shuai Guo1.
Abstract
Aims: To develop and validate a nomogram prediction model for the risk of diabetic foot in patients with type 2 diabetes mellitus (T2DM) and evaluate its clinical application value.Entities:
Keywords: diabetic foot; individual risk prediction model; nomogram; orthopedics; type 2 diabetes mellitus (T2DM)
Mesh:
Year: 2022 PMID: 35909507 PMCID: PMC9325991 DOI: 10.3389/fendo.2022.890057
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 6.055
Figure 1Flowchart of patients included in this study.
Characteristics of the patients in the training cohort and validation cohort.
| Characteristics | Training cohort (n=1365) | Validation cohort (n=585) | t/Z/χ2 |
|
|---|---|---|---|---|
| Gender [n(%)] | 0.845 | 0.358 | ||
| Male | 863 (63.2) | 357 (61.0) | ||
| Female | 502 (36.8) | 228 (39.0) | ||
| Age (year) | 46.79±2.71 | 45.12±2.70 | 0.533 | 0.601 |
| Course of disease (year) | 19.79±1.93 | 19.10±2.51 | 1.071 | 0.298 |
| BMI [n(%)] | 2.108 | 0.349 | ||
| <18.5kg/m2 | 109 (8.0) | 53 (9.1) | ||
| 18.5-24 kg/m2 | 846 (62.0) | 374 (63.9) | ||
| >24 kg/m2 | 410 (30.0) | 158 (27.0) | ||
| OGTT 2h (mmol/L) | 14.05±1.85 | 13.90±1.57 | 0.441 | 0.664 |
| HbA1c (%) | 10.17±0.96 | 10.14±0.98 | 0.679 | 0.506 |
| LDL (mmol/L) | 3.73±1.04 | 3.79±0.90 | 1.341 | 0.180 |
| TG [n(%)] | 2.213 | 0.331 | ||
| <1.7 mmol/L | 478 (35.0) | 193 (33.0) | ||
| 1.7-2.3 mmol/L | 315 (23.1) | 153 (26.2) | ||
| >2.3 mmol/L | 572 (41.9) | 239 (40.8) | ||
| TC (mmol/L) | 5.56±1.00 | 5.58±0.97 | 0.478 | 0.633 |
| Smoke [n(%)] | 0.244 | 0.622 | ||
| No | 546 (40.0) | 241 (41.2) | ||
| Yes | 819 (60.0) | 344 (58.8) | ||
| Drink [n(%)] | 0.963 | 0.327 | ||
| No | 642 (47.0) | 261 (44.6) | ||
| Yes | 723 (53.0) | 324 (55.4) | ||
| Hypertension [n(%)] | 0.876 | 0.349 | ||
| No | 802 (58.8) | 357 (61.0) | ||
| Yes | 563 (41.2) | 228 (39.0) | ||
| Family history of type 2 diabetes [n(%)] | 0.702 | 0.402 | ||
| No | 328 (24.0) | 151 (25.8) | ||
| Yes | 1037 (76.0) | 434 (74.2) | ||
| Exercise [n(%)] | 1.222 | 0.269 | ||
| No | 892 (65.3) | 367 (62.7) | ||
| Yes | 473 (34.7) | 218 (37.3) |
BMI, Body Mass Index; OGTT, Oral Glucose Tolerance Test; HbA1c, Hemoglobin A1c; LDL, Low-Density Lipoprotein; TG, Triglyceride; TC, Total Cholesterol.
Univariate logistic regression analysis of patients in the training cohort.
| Characteristics | Diabetic foot group (n=203) | Non-diabetic foot group (n=1162) | t/Z/χ2 |
|
|---|---|---|---|---|
| Gender [n(%)] | 1.001 | 0.317 | ||
| Male | 122(60.1) | 741(63.8) | ||
| Female | 81(39.9) | 421(36.2) | ||
| Age (year) | 47.22±2.98 | 46.71±2.65 | 6.081 | 0.014 |
| Course of disease (year) | 20.09±2.00 | 19.73±1.91 | 5.848 | 0.016 |
| BMI [n(%)] | 6.426 | 0.011 | ||
| <18.5kg/m2 | 15(7.4) | 94(8.1) | ||
| 18.5-24 kg/m2 | 109(53.7) | 737(63.4) | ||
| >24 kg/m2 | 79(38.9) | 331(28.5 ) | ||
| OGTT 2h (mmol/L) | 14.16±1.98 | 14.03±1.83 | 0.877 | 0.349 |
| HbA1c (%) | 10.86±0.97 | 10.05±0.91 | 112.052 | <0.001 |
| LDL (mmol/L) | 4.19±0.83 | 3.65±1.06 | 42.974 | <0.001 |
| TG [n(%)] | 2.193 | 0.139 | ||
| <1.7 mmol/L | 59(29.1) | 419(36.0) | ||
| 1.7-2.3 mmol/L | 54(26.6) | 261(22.5) | ||
| >2.3 mmol/L | 90(44.3) | 482(41.5) | ||
| TC (mmol/L) | 5.99±0.75 | 5.48±1.02 | 41.716 | <0.001 |
| Smoke [n(%)] | 6.271 | 0.012 | ||
| No | 65(32.0) | 481(41.4) | ||
| Yes | 138(68.0) | 681(58.6) | ||
| Drink [n(%)] | 7.032 | 0.008 | ||
| No | 78(38.4) | 564(48.5) | ||
| Yes | 125(61.6) | 598(51.5) | ||
| Hypertension [n(%)] | 1.263 | 0.261 | ||
| No | 112(55.2) | 690(59.4) | ||
| Yes | 91(44.8) | 472(40.6) | ||
| Family history of type 2 diabetes [n(%)] | 0.565 | 0.452 | ||
| No | 53(26.1) | 275(23.7) | ||
| Yes | 150(73.9) | 887(76.3) | ||
| Exercise [n(%)] | 1.132 | 0.287 | ||
| No | 126(62.1) | 766(65.9) | ||
| Yes | 77(37.9) | 396(34.1) |
BMI, Body Mass Index; OGTT, Oral Glucose Tolerance Test; HbA1c, Hemoglobin A1c; LDL, Low-Density Lipoprotein; TG, Triglyceride; TC, Total Cholesterol.
Multivariate logistic regression analysis of patients in the training cohort.
| Variable | B | SE | Wald | OR | 95%CI |
|
|---|---|---|---|---|---|---|
| Age(year) | 0.098 | 0.031 | 9.855 | 1.103 | 1.038-1.173 | 0.002 |
| HbA1c (%) | 0.920 | 0.092 | 100.327 | 2.509 | 2.096-3.004 | <0.001 |
| LDL (mmol/L) | 0.585 | 0.096 | 37.078 | 1.796 | 1.487-2.168 | <0.001 |
| TC(mmol/L) | 0.524 | 0.098 | 28.877 | 1.690 | 1.395-2.046 | <0.001 |
| Smoke | 0.431 | 0.179 | 5.813 | 1.539 | 1.084-2.186 | 0.016 |
| Drink | 0.341 | 0.172 | 3.931 | 1.407 | 1.004-1.971 | 0.047 |
| Constant | -21.765 | 2.041 | 113.677 | 0.000 | – | <0.001 |
HbA1c, Hemoglobin A1c; LDL, Low-Density Lipoprotein; TC, Total Cholesterol.
Figure 2Nomogram prediction for the risk of diabetic foot in patients with T2DM.
Figure 3ROC curves of the nomogram prediction for the risk of diabetic foot in patients with T2DM in the training cohort (A) and validation cohort (B).
Figure 4Calibration plots of the nomogram prediction for the risk of diabetic foot in patients with T2DM in the training cohort (A) and validation cohort (B).
Figure 5DCA curves of the nomogram prediction for the risk of diabetic foot in patients with T2DM in the training cohort (A) and validation cohort (B).
Figure 6Visualization application of the nomogram prediction for the risk of diabetic foot in patients with T2DM.